Naringenin's potential antibacterial and antifungal behaviour has been investigated. In 1987, it was reported that naringenin had no antibacterial activity against Staphylococcus epidermidis .  This finding was not replicated in a 2000 study in which naringenin was shown to indeed have an antimicrobial effect on S. epidermidis , as well as Staphylococcus aureus , Bacillus subtilis , Micrococcus luteus , and Escherichia coli .  Further research has added evidence for antimicrobial effects against Lactococcus lactis ,  lactobacillus acidophilus , Actinomyces naeslundii , Prevotella oralis , Prevotella melaninogencia , Porphyromonas gingivalis ,  as well as yeasts such as Candida albicans , Candida tropicalis , and Candida krusei .  There is also evidence of antibacterial effects on H. pylori , though naringenin has not been shown to have any inhibition on urease activity of the microbe. 
Five cases of hepatotoxicity or liver failure , two of which resulted in death, have been reported with bicalutamide.   Symptoms that may indicate liver dysfunction include nausea, vomiting, abdominal pain, fatigue, anorexia , "flu-like" symptoms , dark urine , and jaundice .  Bicalutamide has also been associated with several case reports of interstitial pneumonitis , which can potentially progress to pulmonary fibrosis .    Symptoms that may indicate lung dysfunction include dyspnea (difficult breathing or shortness of breath), cough, and pharyngitis ( inflammation of the pharynx , resulting in sore throat ).  Both hepatotoxicity and interstitial pneumonitis are said to be extremely rare events with bicalutamide.    A few cases of photosensitivity have been reported with bicalutamide.  Hypersensitivity reactions ( drug allergy ) like angioedema and hives have also uncommonly been reported in association with bicalutamide.  Because it is an antiandrogen, bicalutamide has a theoretical risk of birth defects like ambiguous genitalia and brain feminization in male fetuses .